Profile data is unavailable for this security.
About the company
Werewolf Therapeutics, Inc. is a biopharmaceutical company engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. It is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. It is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.
- Revenue in USD (TTM)0.00
- Net income in USD-72.84m
- Incorporated2017
- Employees39.00
- LocationWerewolf Therapeutics Inc200 Talcott Avenue, 2Nd FloorWATERTOWN 02472United StatesUSA
- Phone+1 (617) 952-0555
- Fax+1 (302) 655-5049
- Websitehttps://werewolftx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AN2 Therapeutics Inc | 0.00 | -33.99m | 29.05m | 22.00 | -- | 0.4805 | -- | -- | -1.13 | -1.13 | 0.00 | 2.21 | 0.00 | -- | -- | 0.00 | -41.21 | -53.41 | -45.91 | -58.50 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.72 | -- | -- | -- |
| Rein Therapeutics Inc | 0.00 | -58.89m | 29.44m | 11.00 | -- | 23.76 | -- | -- | -2.63 | -2.63 | 0.00 | 1.84 | 0.00 | -- | -- | 0.00 | -74.57 | -64.62 | -80.38 | -71.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -299.71 | -- | -- | -- |
| Harvard Apparatus Regenertv Tchnlgy Inc | 743.00k | -6.53m | 29.53m | 8.00 | -- | 19.00 | -- | 39.75 | -0.4029 | -0.4029 | 0.0459 | 0.0905 | 0.1891 | 9.21 | 371.50 | 92,875.00 | -166.09 | -292.39 | -227.59 | -1,068.06 | 16.29 | -- | -878.20 | -6,677.86 | 1.83 | -- | 0.00 | -- | 317.48 | -- | 14.30 | -- | -- | -- |
| Dyadic International Inc | 3.34m | -7.35m | 30.04m | 6.00 | -- | 11.52 | -- | 8.99 | -0.2371 | -0.2371 | 0.1077 | 0.072 | 0.2974 | -- | 5.27 | 557,033.30 | -65.38 | -46.12 | -89.89 | -51.96 | 31.54 | 35.01 | -219.86 | -335.59 | -- | -34.44 | 0.6579 | -- | 20.58 | 15.77 | 14.51 | -- | -- | -- |
| Lantern Pharma Inc | 0.00 | -18.92m | 30.20m | 24.00 | -- | 3.11 | -- | -- | -1.75 | -1.75 | 0.00 | 0.8684 | 0.00 | -- | -- | 0.00 | -86.16 | -32.94 | -104.31 | -34.72 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.20 | -- | 17.11 | -- |
| Reviva Pharmaceuticals Holdings Inc | 0.00 | -22.76m | 30.45m | 14.00 | -- | 5.52 | -- | -- | -0.4722 | -0.4722 | 0.00 | 0.0472 | 0.00 | -- | -- | 0.00 | -207.23 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.79 | -- | -- | -- |
| Neurosense Therapeutics Ltd | 0.00 | -8.66m | 30.89m | 15.00 | -- | -- | -- | -- | -0.361 | -0.361 | 0.00 | -0.0211 | 0.00 | -- | -- | 0.00 | -491.23 | -145.64 | -- | -198.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.02 | -- | -15.59 | -- |
| Palatin Technologies Inc | 8.85m | -4.81m | 31.07m | 29.00 | -- | 42.71 | -- | 3.51 | -13.52 | -13.52 | 12.39 | 0.4073 | 1.47 | -- | -- | 305,087.90 | -79.90 | -79.95 | -- | -118.70 | 0.00 | 91.70 | -54.32 | -1,326.05 | -- | -- | 0.00 | -- | -100.00 | -- | 41.80 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -36.05m | 31.14m | 24.00 | -- | 1.65 | -- | -- | -10.40 | -10.40 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -141.49 | -63.01 | -215.46 | -80.57 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -41.88 | -- | 1.85 | -- |
| Werewolf Therapeutics Inc | 0.00 | -72.84m | 31.73m | 39.00 | -- | 1.04 | -- | -- | -1.62 | -1.62 | 0.00 | 0.6264 | 0.00 | -- | -- | 0.00 | -66.32 | -33.10 | -76.84 | -36.81 | -- | -- | -- | -593.05 | -- | -54.29 | 0.4829 | -- | -90.55 | -- | -88.70 | -- | -0.919 | -- |
| Jasper Therapeutics Inc | 0.00 | -91.02m | 31.90m | 64.00 | -- | 2.76 | -- | -- | -5.90 | -5.90 | 0.00 | 0.4135 | 0.00 | -- | -- | 0.00 | -116.04 | -75.11 | -147.54 | -86.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.55 | -- | -- | -- |
| Atara Biotherapeutics Inc | 151.93m | 23.40m | 32.09m | 38.00 | 2.03 | -- | 1.21 | 0.2112 | 2.19 | 2.19 | 12.81 | -5.08 | 1.76 | 3.99 | 93.55 | 993,006.60 | 27.07 | -67.79 | -- | -93.07 | 81.63 | -- | 15.40 | -558.47 | 1.02 | 15.24 | 8.31 | -- | 1,404.02 | -- | 69.07 | -- | -46.73 | -- |
| Onkure Therapeutics Inc | 0.00 | -81.21m | 32.79m | 46.00 | -- | 0.4936 | -- | -- | -12.78 | -12.78 | 0.00 | 4.90 | 0.00 | -- | -- | 0.00 | -107.93 | -48.73 | -115.20 | -53.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 31.94 | -- | 49.34 | -- |
| Promis Neurosciences Inc | 0.00 | -29.28m | 32.82m | 6.00 | -- | 3.57 | -- | -- | -18.62 | -18.62 | 0.00 | 4.27 | 0.00 | -- | -- | -- | -127.41 | -85.65 | -188.18 | -145.08 | -- | -- | -- | -3,184,250.00 | -- | -- | 0.00 | -- | -- | -- | 121.03 | -- | -- | -- |
| Bioqual Inc | 46.54m | 453.25k | 33.55m | 108.00 | 74.02 | 0.938 | 12.22 | 0.7209 | 0.5068 | 0.5068 | 52.03 | 39.99 | 0.7111 | -- | 3.19 | -- | 0.6926 | 4.12 | 0.7745 | 4.83 | 12.85 | 16.15 | 0.974 | 4.03 | -- | -- | 0.00 | 32.81 | -16.60 | 1.06 | -316.79 | -- | -36.99 | -6.51 |
| Cell Source Inc | 0.00 | -6.57m | 34.03m | -- | -- | -- | -- | -- | -0.1613 | -0.1613 | 0.00 | -0.4379 | 0.00 | -- | -- | -- | -2,039.39 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -3.74 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Werewolf Therapeutics Inc's reporting currency: US Dollar USD
25.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 04 Nov 2025 | 6.68m | 13.76% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.22m | 2.51% |
| BofA Securities, Inc.as of 30 Sep 2025 | 1.15m | 2.37% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 677.77k | 1.40% |
| Sphera Funds Management Ltd.as of 30 Sep 2025 | 626.81k | 1.29% |
| DC Investments Management LLCas of 31 Dec 2025 | 589.10k | 1.21% |
| Bank of America, NA (Private Banking)as of 30 Sep 2025 | 509.40k | 1.05% |
| PFM Health Sciences LPas of 30 Sep 2025 | 401.11k | 0.83% |
| Geode Capital Management LLCas of 31 Dec 2025 | 335.89k | 0.69% |
| Millennium Management LLCas of 30 Sep 2025 | 317.05k | 0.65% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
